Rekombinanter CD274 (Avelumab Biosimilar) Antikörper

Produktnummer ABIN7200665

Dieser Humanized Monoklonal Antikörper erkennt spezifisch CD274 (Avelumab Biosimilar) in FACS und in vivo. Er zeigt eine Reaktivität gegenüber Human.

Kurzübersicht für Rekombinanter CD274 (Avelumab Biosimilar) Antikörper (ABIN7200665)

Target: CD274 (Avelumab Biosimilar)

Antikörpertyp: Recombinant Antibody

Reaktivität: Human

Wirt: Humanized

Klonalität: Monoklonal

Konjugat: Dieser CD274 (Avelumab Biosimilar) Antikörper ist unkonjugiert

Applikation: Flow Cytometry (FACS), In vivo Studies (in vivo)

Güteklasse: Research Grade

Produktdetails anti-CD274 (Avelumab Biosimilar) Antikörper

Verwendungszweck: Avelumab Biosimilar, Human PD-L1 Monoclonal Antibody

Spezifität: The in vivo grade avelumab biosimilar specifically binds to the programmed death ligand 1 (PD-L1), blocking its interaction with PD-1 and B7-1.

Produktmerkmale: What is Avelumab biosimilar research grade? Avelumab is a humanized monoclonal antibody directed against the human protein ligand PD-L1 (B7-H1 or CD274, programmed cell death ligand 1), with potential antibody-dependent cell-mediated cytotoxicity property. Avelumab is used for the treatment of several kinds of carcinoma. Avelumab biosimilar uses the same protein sequences as the therapeutic antibody of Avelumab. PD-L1 (B7-H1 or CD274, programmed cell death ligand 1) and PD-L2 (B2-DC or CD273, programmed cell death ligand 2) are the two ligands for the receptor PD-1 (CD279, programmed death 1). PD-L1 is an immune checkpoint molecule expressed on both tumor cells and certain immune cells. The binding of PD-L1 to its receptors PD-1 or B7.1 on activated T cells causes an inhibitory signal to suppress their production in the lymph nodes, thereby preventing immune responses to events such as pregnancy or autoimmune disease. This pathway is also utilized by cancer cells to evade the immune system through evasion of anti-tumor T-cell response. Furthermore, over-expression of PD-L1 and PD-1 has been linked to increased tumor aggressiveness and poorer prognosis. Avelumab binds directly and selectively to PD-L1 and blocks interaction with both PD-1 and B7.1 receptors, thus reinvigorates and enhances the body's adaptive anti-cancer activity. Disrupting the PD-L1/B7.1 interaction may also enhance T-cell priming, which could result in increased duration of response and survival.

Aufreinigung: Protein A or G affinity column

Reinheit: >95 % by reducing SDS-PAGE

Sterilität: 0.2 μm filtered

Endotoxin-Niveau: < 1 EU per 1 mg of the protein by the LAL method

Immunogen: The anti-human PD-L1 monoclonal antibody avelumab biosimilar was produced in the avelumab biosimilar Chinese Hamster Ovary (CHO) stable cell line.

Isotyp: IgG1

Anwendungsinformationen

Applikationshinweise: ELISA, neutralization, functional assays such as bioanalytical PK and ADA assays, and those assays for studying biological pathways affected by avelumab.

Beschränkungen: Nur für Forschungszwecke einsetzbar

Handhabung

Format: Liquid

Konzentration: > 3 mg/mL

Buffer: PBS, pH 7.4, no stabilizers or preservatives.

Konservierungsmittel: Without preservative

Lagerung: 4°C,-20 °C

Informationen zur Lagerung: 12 months from date of receipt, -20 to -70°C as supplied. 1 month from date of receipt, 2 to 8°C as supplied.

Haltbarkeit: 12 months

Details zu CD274 (Avelumab Biosimilar)

Target: CD274 (Avelumab Biosimilar)

Andere Bezeichnung: Avelumab Biosimilar

Substanzklasse: Biosimilar